Homologous recombination deficiency and glycolysis-related pathway in adjuvant chemotherapy for triple-negative breast cancer: A genomic landscape and biomarker assessment of the PATTERN trial.

There was a borderline significant difference in RFS between the PCb arm and the CEF‐T arm in patients whose values were above the median (Figure 2C HR = 0.26, 95% CI 0.06–1.20, p = 0.06), while the outcome of the two cohorts was similar in the rest (Figure 2D HR = 0.97, 95% CI 0.31–3.04, p = 0.96).

also in 11,409 other papers